What is KamTek?
Established in 1992, KamTek has evolved into a cornerstone of the biotech and healthcare ecosystem. The company specializes in high-integrity biorepository services, cryopreservation, and molecular biology support, catering to a prestigious client base that includes the FDA, NIH, and leading academic institutions. With over three decades of operational excellence, KamTek provides the essential infrastructure required for drug discovery and complex clinical trials. Their commitment to compliance and secure sample management positions them as a vital partner for organizations navigating the rigorous demands of modern life sciences research.
How much funding has KamTek raised?
KamTek has raised a total of $44K across 1 funding round:
Debt
$44K
Debt (2021): $44K with participation from PPP
Key Investors in KamTek
PPP
Public-Private Partnership
What's next for KamTek?
With the infusion of this recent capital, KamTek is well-positioned to scale its laboratory operations and enhance its technological capabilities in sample management. The company is expected to focus on expanding its footprint within the clinical trial support market, where demand for secure, compliant, and scalable biorepository services continues to rise. By investing in advanced laboratory solutions, KamTek will likely strengthen its competitive advantage, ensuring it remains a trusted partner for global research entities as they accelerate their drug development pipelines and regulatory submissions.
See full KamTek company page
